| 000 | 01722 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250513144531.0 | ||
| 264 | 0 | _c19980910 | |
| 008 | 199809s 0 0 eng d | ||
| 022 | _a0923-7534 | ||
| 024 | 7 |
_a10.1023/a:1008232514137 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBozec, L | |
| 245 | 0 | 0 |
_aIrinotecan-induced immune thrombocytopenia. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _cApr 1998 |
||
| 300 |
_a453-5 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xdiagnosis |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBlood Platelets _ximmunology |
| 650 | 0 | 4 |
_aCamptothecin _xadverse effects |
| 650 | 0 | 4 |
_aColonic Neoplasms _xdiagnosis |
| 650 | 0 | 4 |
_aFluorouracil _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xanalysis |
| 650 | 0 | 4 | _aIrinotecan |
| 650 | 0 | 4 |
_aLeucovorin _xadministration & dosage |
| 650 | 0 | 4 |
_aLiver Neoplasms _xsecondary |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOrganoplatinum Compounds _xadministration & dosage |
| 650 | 0 | 4 | _aOxaliplatin |
| 650 | 0 | 4 |
_aThrombocytopenia _xchemically induced |
| 700 | 1 | _aBierling, P | |
| 700 | 1 | _aFromont, P | |
| 700 | 1 | _aLévi, F | |
| 700 | 1 | _aDebat, P | |
| 700 | 1 | _aCvitkovic, E | |
| 700 | 1 | _aMisset, J L | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 9 _gno. 4 _gp. 453-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1023/a:1008232514137 _zAvailable from publisher's website |
| 999 |
_c9603119 _d9603119 |
||